Fluconazole Drug Interactions
Fluconazole interacts with numerous medications through cytochrome P450 enzyme inhibition (particularly CYP2C9, CYP2C19, and CYP3A4), causing clinically significant increases in plasma concentrations of co-administered drugs and risk of QT prolongation when combined with other QT-prolonging agents. 1, 2
Mechanism of Interactions
Fluconazole is a moderate inhibitor of CYP3A4 and CYP2C9, and a strong inhibitor of CYP2C19 2. Among the azole antifungals, fluconazole is the weakest CYP3A4 inhibitor, but its enzyme-inhibiting effects persist for 4-5 days after discontinuation due to its long half-life 2. The dose-dependent nature of these interactions becomes more pronounced at fluconazole doses ≥200 mg daily 3.
Critical Drug Interactions by Category
Cardiovascular Medications
QT-Prolonging Drugs:
- Amiodarone: Concomitant use increases QT prolongation risk, requiring extreme caution especially with high-dose fluconazole (800 mg) 2
- Fluoroquinolones, macrolides (clarithromycin, erythromycin), ondansetron: Combined use significantly increases cardiotoxicity risk including torsade de pointes and sudden cardiac death 1, 4
- The erythromycin-fluconazole combination should be avoided entirely 2
Calcium Channel Blockers:
- Nifedipine, isradipine, amlodipine, verapamil, felodipine: Fluconazole increases systemic exposure, requiring frequent monitoring for adverse events 2
Anticoagulants
Warfarin and coumarin-type anticoagulants:
- Fluconazole inhibits CYP2C9, causing increased prothrombin time and bleeding risk (bruising, epistaxis, GI bleeding, hematuria, melena) 4, 2
- Careful monitoring of prothrombin time is mandatory; warfarin dose adjustment is typically necessary 2
Immunosuppressants
Calcineurin inhibitors and mTOR inhibitors:
- Cyclosporine, tacrolimus, sirolimus: Fluconazole commonly elevates serum levels through CYP3A4 inhibition 3, 2
- Among azoles, fluconazole causes the least CYP3A4 inhibition, but interactions remain clinically significant 3
- Close therapeutic drug monitoring is essential; antirejection medication doses typically require reduction 3
- The interaction is dose-dependent and more pronounced at fluconazole doses ≥200 mg daily 3
Chemotherapy Agents
- Nilotinib (chronic myeloid leukemia): Increased QT prolongation risk 1
- Panobinostat (myeloma): Drug interaction concerns 1
- Cyclophosphamide: Combination increases serum bilirubin and creatinine; use with caution 2
Central Nervous System Medications
Benzodiazepines:
- Midazolam: Fluconazole increases plasma concentrations through CYP3A4 inhibition 2
Antidepressants:
- Amitriptyline, nortriptyline: Fluconazole enhances effects; measure drug levels at therapy initiation and after 1 week, adjust doses accordingly 2
Anticonvulsants:
- Carbamazepine: 30% increase in serum carbamazepine levels; risk of toxicity requiring dose adjustment based on concentration monitoring 2
- Phenytoin: Increased phenytoin levels requiring monitoring 2
Analgesics
Alfentanil: Reduced clearance and prolonged half-life; dosage adjustment may be necessary 2
Urological Medications
Abrocitinib: Significantly increased systemic exposure; avoid concomitant use 2
Celecoxib: 68% increase in Cmax and 134% increase in AUC; consider reducing celecoxib dose by half 2
Other Azole Antifungals
Fluconazole itself can interact when combined with itraconazole, creating contraindicated drug-drug interactions 5
Clinical Management Principles
Key monitoring requirements:
- Therapeutic drug monitoring is not required for fluconazole due to linear pharmacokinetics, except in renal failure where dose modification is needed 1
- The extensive list of drug-drug interactions continues to expand 1
- Consultation with an infectious disease expert is recommended before incorporating azoles into treatment regimens 1
Common pitfalls:
- Forgetting that enzyme inhibition persists 4-5 days post-discontinuation 2
- Failing to adjust doses of interacting medications when starting or stopping fluconazole
- Underestimating the cumulative QT prolongation risk when multiple interacting drugs are prescribed
- Not accounting for the dose-dependent nature of interactions (≥200 mg daily threshold) 3
Special populations: